Skip to main content
Figure 2 | BMC Infectious Diseases

Figure 2

From: Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

Figure 2

HI antibody GMTs stratified by age (per-protocol immunogenicity sub-cohort). Footnote: CI, confidence interval; GMT, geometric mean titer; QIV, inactivated quadrivalent influenza vaccine; TIV-Vic, inactivated trivalent influenza vaccine Victoria lineage B strain; TIV-Yam, inactivated trivalent influenza vaccine Yamagata lineage B strain.

Back to article page
\